SCHEMBL3276608

SCHEMBL3276608

Clc1cccc2scc(CBr)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.41
ALDH1A1 P00352 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
CYP2A6 P11509 3/20 0.36
DRD2 P14416 2/20 0.36
DRD3 P35462 2/20 0.36
DRD4 P21917 1/20 0.36
MAPK1 P28482 2/20 0.34
MCL1 Q07820 1/20 0.34
OGG1 O15527 1/20 0.34
GPR84 Q9NQS5 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
CA1 P00915 1/20 0.32
PNMT P11086 1/20 0.31
KDM4E B2RXH2 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
PSMB8 P28062 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10692123 0.85 CYP2A6 (0.36) CA2ALDH1A1CYP1A2CYP2D6CYP2C19
SCHEMBL15729955 0.81 CYP2A6 (0.53) CA2ALDH1A1CYP1A2CYP2D6CYP2C19
SCHEMBL6002815 0.81 ALDH1A1 (0.39) CA2ALDH1A1CYP1A2CYP2D6CYP2C19
SCHEMBL2090743 0.81 CYP2A6 (0.36) CA2ALDH1A1CYP1A2CYP2D6CYP2C19
SCHEMBL8584219 0.79 TAAR1 (0.50) CA2CYP2A6DRD2DRD3DRD4
SCHEMBL3539594 0.78 CTSG (0.43) CA2ALDH1A1CYP1A2CYP2D6CYP2C19
SCHEMBL5177565 0.78 CA2 (0.41) CA2ALDH1A1CYP1A2CYP2D6CYP2C19
SCHEMBL28843681 0.76 CA2 (0.38) CA2ALDH1A1CYP1A2CYP2D6CYP2C19
SCHEMBL3150930 0.76 LMNA (0.41) ALDH1A1CYP1A2CYP2A6DRD2DRD3
SCHEMBL5177196 0.74 CA2 (0.38) CA2ALDH1A1CYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1792614-A1 Benzo[b]thiophene derivatives Teijin Pharma Limited (JP) 2007-06-06 EP claimed
EP-1966134-B1 NOVEL FUSED PYRROLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-03-12 EP disclosed
US-7696240-B2 Fused pyrrole derivatives HOFFMANN-LA ROCHE INC. (US) 2010-04-13 US disclosed
EP-1966134-A1 NOVEL FUSED PYRROLE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-09-10 EP disclosed
WO-2007068621-A1 NOVEL FUSED PYRROLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-06-21 WO disclosed
US-20070142452-A1 Fused pyrrole derivatives HOFFMANN-LA ROCHE INC. 2007-06-21 US disclosed
EP-1792614-A1 Benzo[b]thiophene derivatives Teijin Pharma Limited (JP) 2007-06-06 EP disclosed
EP-0151477-B1 1H-IMIDAZOLE DERIVATIVES, A PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FERRER INTERNACIONAL, S.A. (ES) 1990-09-12 EP disclosed
EP-0151477-A2 1H-Imidazole derivatives, a process for preparing them and pharmaceutical compositions containing them FERRER INTERNACIONAL, S.A. (ES) 1985-08-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142452-A1 Fused pyrrole derivatives CMA1, PREP, CPA3 CA2 121/4885ALDH1A1 827/4885CYP1A2 580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.